SCHEMBL6418326

SCHEMBL6418326

Oc1ccc(C=NNc2nc3nonc3nc2Nc2ccc(F)c(Cl)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.47
SMN1; SMN2 Q16637 5/20 0.42
NPC1 O15118 1/20 0.42
PKM P14618 1/20 0.42
RAB9A P51151 1/20 0.42
ENPP2 Q13822 3/20 0.42
MAPT P10636 7/20 0.41
TP53 P04637 3/20 0.41
POLB P06746 1/20 0.41
CCR2 P41597 1/20 0.41
CCR5 P51681 1/20 0.41
EGFR P00533 4/20 0.40
RXFP1 Q9HBX9 1/20 0.39
KMT2A Q03164 4/20 0.38
MEN1 O00255 2/20 0.38
LMNA P02545 2/20 0.38
MAPK1 P28482 1/20 0.38
GRM4 Q14833 1/20 0.38
ALDH1A1 P00352 2/20 0.37
KDR P35968 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6432172 0.91 GAA (0.47) GAASMN1; SMN2NPC1PKMRAB9A
SCHEMBL6440252 0.89 MAPT (0.44) GAASMN1; SMN2NPC1PKMRAB9A
SCHEMBL6417027 0.88 TDP1 (0.47) GAASMN1; SMN2NPC1PKMRAB9A
SCHEMBL6440416 0.87 MEN1 (0.47) GAASMN1; SMN2NPC1PKMRAB9A
SCHEMBL6418252 0.85 RRM1 (0.49) GAASMN1; SMN2NPC1PKMRAB9A
SCHEMBL6435805 0.85 MAPT (0.46) GAASMN1; SMN2NPC1PKMRAB9A
SCHEMBL6419259 0.84 SMN1; SMN2 (0.42) SMN1; SMN2NPC1RAB9AMAPTTP53
SCHEMBL6419770 0.84 DDX3X (0.45) GAASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL6415698 0.82 NPC1 (0.47) GAASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL6432545 0.81 APP (0.42) GAASMN1; SMN2NPC1PKMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 GAA 3186/4885SMN1; SMN2 4369/4885NPC1 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.